Invention Grant
- Patent Title: Genetically modified mice and engraftment
- Patent Title (中): 转基因小鼠和植入物
-
Application No.: US13617472Application Date: 2012-09-14
-
Publication No.: US08692052B2Publication Date: 2014-04-08
- Inventor: Sean Stevens , Andrew J. Murphy , Richard Flavell , Elizabeth Eynon , Jorge Galan , Tim Willinger , Markus Manz , Anthony Rongvaux , George D. Yancopoulos
- Applicant: Sean Stevens , Andrew J. Murphy , Richard Flavell , Elizabeth Eynon , Jorge Galan , Tim Willinger , Markus Manz , Anthony Rongvaux , George D. Yancopoulos
- Applicant Address: US NY Tarrytown US CT New Haven CH Bellinzona
- Assignee: Regeneron Pharmaceuticals,Yale University,Institute for Research in Biomedicine (IRB)
- Current Assignee: Regeneron Pharmaceuticals,Yale University,Institute for Research in Biomedicine (IRB)
- Current Assignee Address: US NY Tarrytown US CT New Haven CH Bellinzona
- Agent Tor Smeland; Margarita Zippin; Elizabeth A. Alcamo
- Main IPC: A01K67/033
- IPC: A01K67/033 ; G01N33/00

Abstract:
A mouse with a humanization of the mIL-3 gene and the mGM-CSF gene, a knockout of a mRAG gene, and a knockout of a mII2rg subunit gene; and optionally a humanization of the TPO gene is described. A RAG/II2rg KO/hTPO knock-in mouse is described. A mouse engrafted with human hematopoietic stem cells (HSCs) that maintains a human immune cell (HIC) population derived from the HSCs and that is infectable by a human pathogen, e.g., S. typhi or M. tuberculosis is described. A mouse that models a human pathogen infection that is poorly modeled in mice is described, e.g., a mouse that models a human mycobacterial infection, wherein the mouse develops one or more granulomas comprising human immune cells. A mouse that comprises a human hematopoietic malignancy that originates from an early human hematopoietic cells is described, e.g., a myeloid leukemia or a myeloproliferative neoplasia.
Public/Granted literature
- US20130022996A1 GENETICALLY MODIFIED MICE AND ENGRAFTMENT Public/Granted day:2013-01-24
Information query